Back to today’s briefing

Story perspectives

Revolutionary Retinal Treatments Unveiled at CRU 2025 Conference

4/10/2025

50 6

Summary

Bayer Advances Retinal Treatments

At the CRU 2025 conference in Napa, California, experts unveiled groundbreaking advancements in retinal treatments, spotlighting innovative anti-VEGF therapies and gene therapy. Bayer's application to the EMA for aflibercept 8mg promises to ease the burden of frequent injections for patients with retinal vein occlusion, paving the way for a brighter future in patient care.

Summary

Opus Genetics Innovates

Opus Genetics has unveiled promising results from its Phase 1/2 trial of OPGx-LCA5, a groundbreaking gene therapy for Leber congenital amaurosis (LCA) 5. A 16-year-old participant experienced remarkable vision enhancement within just a month, all without any side effects. With plans for a registrational trial in 2026, the company is on the path to seeking FDA approval for this rare retinal disease.

1 of 2

Bayer Advances Retinal Treatments

At the CRU 2025 conference in Napa, California, experts unveiled groundbreaking advancements in retinal treatments, spotlighting innovative anti-VEGF therapies and gene therapy. Bayer's application to the EMA for aflibercept 8mg promises to ease the burden of frequent injections for patients with retinal vein occlusion, paving the way for a brighter future in patient care.

1 / 2